Author: Mark Du Bois

Connect with Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall at BIO-Europe Nov 6-8, Munich, to discover our unique formulation and drying technology LaminarPace, new external validation of our data, and our most recent deal with a major American Biomanufacturing organization.

Ziccum’s game-changing system LaminarPace transforms delicate liquid biotherapeutics into robust bioactive dry powder, with no extreme temperatures, stress or degradation, setting it apart from all other legacy drying systems.

To discuss expanding what’s  possible for your next-generation vaccines and biologics – meet Ann & Fredrik in Munich, 4-6 November.

Contact Ziccum here.

LaminarPace, Ziccum’s unique drying and formulation technology for biologics, has been featured in “Spray Drying of Vaccines – from Laboratory Research to Industrial Applications” by Dr. Cordin Arpagaus. The book argues that emerging alternative drying technologies like LaminarPace are paving the way for enhanced thermostability and dose delivery possibilities

With exciting evidence and compelling cases, “Spray Drying of Vaccines – from Laboratory Research to Industrial Applications” by Dr. Cordin Arpagaus, argues that new advances in aseptic spray drying technologies represent a paradigm shift for vaccine production. In the book an early iteration of LaminarPace is featured in Chapter 3, “Drying Technologies for Vaccines”.

LaminarPace is unique amongst formulation and drying technologies for biologics. Its Mass Transfer drying technique is able to transform delicate liquid vaccine solutions into stable, bioactive dry powder – without exposing them to extreme temperatures, stress factors or degradation. This sets it apart from legacy pharmaceutical drying systems such as lyophilization (freeze drying).

Read more about our Mass Transfer drying technology here.

Ziccum Scientific Director Fabrice Rose and Quality Specialist Fatemeh Norouzi attended the World Vaccine Congress in Barcelona, October 16 – 19, spreading the word on Ziccum’s unique drying and formulation technology LaminarPace and how it enables new delivery and stability possibilities for next-generation vaccines.

Fatemeh Norouzi: “This was a fascinating event with many standouts – the  presentation by WHO Technical Officer & Project Manager Mateusz Hasso-Agopsowicz highlighting the challenges of needle-delivered vaccines and exploring the advantages of alternative routes such as Nasal and Oral was excellent”.

Ziccum’s LaminarPace dries liquid solution vaccines as dry thermostable powders highly suitable for new dosage forms. “Interest in more stable delivery forms for vaccines was high” says Norouzi ,“but the hottest tickets were without doubt for the mRNA vaccine presentations – for these every seat was taken”.

To read more about how LaminarPace can dry liquid mRNA/LNP solution into dry, stable powder – go here.

To read more about the latest external results validating LaminarPace’s capabilities in mRNA – go here.

. 

In an intensive workshop on Friday October 14 at Ziccum’s facilities in Lund,  Ziccum and its visiting partner team from the  Zurich University of Applied Sciences’ Institute of Computational Physics powered ahead with the cutting-edge project developing 3D modelling and ultimately a Digital Twin of  LaminarPace, Ziccum’s unique formulation and drying technology.

Ziccum CEO Ann Gidner: “Great things happen when great minds come together! We were really happy to have our Swiss partners for 3D-modelling of LaminarPace arrive in Lund for this highly productive workshop”,

See the original LinkedIn posts here and here.

Read more about Ziccum’s 3D modelling and Digital Twin project here.

      .

.